Clinical Trials
13 trialsNCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT05060237 2024-10-17
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT05619471 2024-07-25
VISTA
Enspectra Health
Phase NA Completed
NCT05410964 2024-01-30
VISION
Enspectra Health
Completed
NCT00847912 2021-06-11
VAKCCT
VA Office of Research and Development
Phase 4 Completed
NCT03285477 2021-04-13
AK003
Almirall, S.A.
Phase 3 Completed
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT01425749 2016-04-04
Mel55
University of Virginia
Phase EARLY_PHASE1 Completed
NCT00753415 2015-03-17
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00894647 2010-08-31
Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00668733 2010-07-20
Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year
Graceway Pharmaceuticals, LLC
Completed
NCT00603798 2010-06-29
Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00605176 2010-06-29
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
Graceway Pharmaceuticals, LLC
Phase 3 Completed